Dosage guide
AOD-9604 dosage
AOD-9604 dosing: typical range, frequency, half-life, onset, routes, reconstitution math. Evidence-tiered.
At a glance
- Typical dose
- 0.3mg
- Half-life
- 0.5hr
- Frequency
- daily
- Routes
- subcutaneous
Protocol
- 1
Reconstitute the vial
A typical 5 mg vial reconstituted with 2 mL bacteriostatic water gives 2.5 mg/mL (2500 mcg/mL). A 300 mcg dose equals 12 units on a U100 insulin syringe.
Open tool → - 2
Measure the dose
Typical AOD-9604 dose is 0.3 mg (Anecdotal protocols use 250 to 500 mcg subcutaneously once daily, typically before fasted morning training). Use a weight-based calculator for individual adjustments.
Open tool → - 3
- 4
Cycle if needed
Anecdotal protocols run 8 to 12 weeks on, then 4 weeks off. No controlled human cycling data.
Open tool → - 5
Monitor for side effects
Watch for: injection-site reactions; transient mild headache (anecdotal); minimal in clinical trials. Stop or reduce dose if tolerability breaks down.
Why this dose
Modified C-terminal fragment of human growth hormone proposed to stimulate beta-3 adrenergic receptor signaling in adipocytes, increasing lipolysis and fatty-acid oxidation without engaging the GH receptor or activating IGF-1.
The typical dose (0.3 mg) reflects Anecdotal protocols use 250 to 500 mcg subcutaneously once daily, typically before fasted morning training. Individual response varies with body weight, baseline status, concurrent training, and concurrent medications, so the labeled range is the starting point rather than the prescription.
How to administer
AOD-9604 is administered via the subcutaneous route. Subcutaneous injection into rotated abdominal sites is the standard self-administration approach for peptide protocols; rotate sites to limit local irritation. Use a fresh insulin syringe per dose.
Onset of action runs around 1 hour after administration. Peak effect lands near 2 hours post-dose. Plan the administration window so that peak effect lines up with whatever outcome you are dosing for, whether that is training, sleep, or symptom coverage.
Half-life note: Plasma half-life is short (~30 minutes). Injected SC once daily, typically pre-fasted morning training, in anecdotal protocols.
Cycling and tolerance
Anecdotal protocols run 8 to 12 weeks on, then 4 weeks off. No controlled human cycling data.
The cycling rationale for receptor-active compounds is partly empirical and partly mechanistic: continuous high-dose stimulation can downregulate target receptors or accelerate negative-feedback loops on endogenous production. Built-in off-periods give the system time to resensitize before the next phase, which preserves the effective dose-response over a longer arc.
Effects to expect at typical dose
- Modified 16-amino-acid synthetic fragment of human growth hormone (residues 176-191)
- Preclinical models show lipolytic activity in adipose tissue without GH-axis growth effects
- Phase 2 obesity trial (Heffernan 2001) showed no significant weight-loss difference versus placebo
- Anecdotal protocols use 250 to 500 mcg subcutaneously daily on an empty stomach
- No FDA approval; the obesity drug development program was discontinued in 2007
- Granted GRAS status in some jurisdictions for compounded use; not validated for fat loss in humans
Best-graded outcomes
- C Adipocyte lipolysis (preclinical) : Increased lipolytic activity in animal models (Rodent and ex-vivo adipocyte studies).
- D Cartilage repair (osteoarthritis) : Preclinical only; no human OA outcome trials (Preclinical OA models).
- D Body weight loss in obesity : No significant difference vs placebo (Obese adults, 12 weeks, phase 2 trial).
Side effects and interactions
Common side effects
- injection-site reactions
- transient mild headache (anecdotal)
- minimal in clinical trials
Notable interactions
- beta-blockers (minor): theoretical antagonism of beta-3 adrenergic lipolytic signaling
Lists above cover commonly reported and well-characterized items. They are not exhaustive: review the full AOD-9604 profile and discuss with a clinician familiar with your medication list before starting, particularly if you are on prescription therapy or have a chronic condition.
Regulatory snapshot
- WADA status
- unknown
- DEA / Rx
- Not FDA approved; not scheduled; research-chemical status
- Pregnancy
- Insufficient data; not recommended
- Legal status
- Not FDA approved; research-use-only grey market in most jurisdictions
Do not use if
- pregnancy
- lactation
- no established human safety profile for chronic use
Related calculators
Related research